HbA1c Testing Market Size
Global HbA1c Testing Market reached US$ 2.38 in 2025 and is expected to reach US$ 3.38 billion by 2035, growing at a CAGR of 6.8% during the forecast period 2026-2035.
HbA1c testing products are diagnostic tools designed for the measurement of hemoglobin A1c levels in blood samples. Hemoglobin A1c (HbA1c) is a form of hemoglobin that reflects average blood glucose levels over a period of approximately 2-3 months. HbA1c testing is commonly used in the management and monitoring of diabetes. These testing kits typically include the necessary components for collecting a blood sample and conducting the analysis to quantify the percentage of hemoglobin A1c in the blood.
Elevated HbA1c levels are indicative of poor blood glucose control, which increases the risk of diabetes-related complications such as cardiovascular disease, kidney problems, and nerve damage. Regular HbA1c testing allows for the early identification of individuals at risk, enabling proactive interventions to prevent complications. HbA1c testing helps set realistic and personalized glycemic control goals for individuals with diabetes. The results provide a basis for patient education, empowering individuals to make informed decisions about their lifestyle, medication adherence, and overall diabetes management.
HbA1c Testing Market Key Takeaways
- Market expansion: The global HbA1c testing market is forecast to increase from US$ 2.38 billion in 2025 to US$ 3.38 billion by 2035, reflecting a CAGR of 6.8%.
- Product leadership: The kits segment accounted for 39.7% of the product type segment's market share, highlighting the commercial importance of testing kits in diabetes monitoring.
- Regional concentration: North America held 32.4% of the market in 2025, supported by established diagnostic infrastructure and substantial diabetes care requirements.
- Growth geography: Asia-Pacific is identified as the fastest-growing regional market, presenting opportunities for manufacturers targeting expanding diagnostic access and healthcare infrastructure.
- Decentralized testing: At-home HbA1c collection kits and point-of-care analyzers are extending testing beyond conventional diagnostic laboratories.
- Affordability challenge: High kit prices and equipment maintenance costs can restrict routine testing, creating a need for cost-effective diagnostic solutions.
- Competitive positioning: Abbott, Siemens Healthineers, i-SENS, Roche Diagnostics, and other established diagnostic companies compete through product development, point-of-care platforms, and broader access initiatives.
HbA1c Testing Market Scope and Forecast
Market Scope | Details |
| Market Size in 2025 | US$ 2.38 billion |
| Market Size in 2026 | US$ 2.54 billion |
| Market Size by 2035 | US$ 3.38 billion |
| CAGR (2026–2035) | 6.80% |
| Historic Years | 2023–2024 |
| Base Year | 2025 |
| Forecast Period | 2026–2035 |
| Segments Covered | Product Type, Technology, End User |
| Leading Region | North America |
| Fastest Growing Region | Asia-Pacific |
For more details on this report – Request for Sample
HbA1c Testing Market Dynamics: Drivers
Increasing the availability of home diagnostic tests
The increasing popularity and adoption of home HbA1c testing products can be attributed to several factors, reflecting the broader trends in healthcare and patient preferences. For instance, home care diagnostic tests provide individuals with the ability to monitor specific health parameters without the need for a visit to a healthcare facility. This aligns with the broader trend of consumer-centric healthcare. The COVID-19 pandemic has accelerated the adoption of home care diagnostic tests, particularly for infectious diseases. The need for decentralized testing and reducing the risk of exposure in healthcare settings has driven demand for home-based testing solutions.
Additionally, the rise of product launhes also helps to accelerates the market. For instance, in May 2022, OmegaQuant had introduced the HbA1cblood sugar at-home testing kit, enabling users to test their hemoglobin A1c level to metabolize glucose, according to a press release. Typically, HbA1c testing requires a blood draw and lab analysis, but OmegaQuant’s HbA1c test allows for a simple finger stick so users can take the test on their own time and at their convenience, at home.
Furthermore, in May 2022, Labcorp screening for diabetes easier with the an at-home collection kit through Labcorp OnDemand that measures hemoglobin A1c (HbA1c) from a small blood sample. The Weavr Velvet device separates plasma and red blood cells, which allows a more in-depth, complex analysis of the sample. Thus above factors helps to boost the market growth.
Restraints
High cost of the kits
The cost of HbA1c testing kits can impact their accessibility for individuals, particularly in regions with limited financial resources. In some cases, patients may find it challenging to afford regular testing, leading to delayed or infrequent monitoring of their diabetes. Healthcare systems may face budget constraints, especially in resource-limited settings.
The cost of purchasing and maintaining HbA1c testing equipment can strain healthcare budgets, limiting the widespread availability of these kits in certain regions. Accessibility to HbA1c testing kits may be influenced by insurance coverage. In regions where insurance coverage is limited or where certain populations have inadequate insurance, individuals may face barriers to accessing these kits due to high out-of-pocket expenses.
Companies often invest in marketing and sales efforts to promote and sell their HbA1c testing kits. These expenses, including advertising, distribution networks, and sales personnel, are factored into the overall cost structure. For instance, the A1CNow Self Check HbA1c Test Kit preice ranges in between $64.95-$72.33. Thus due to the high cost of the testing kits will restrain the market growth.
HbA1c Testing Market Segment Analysis
The global HbA1c testing Market is segmented based on product type, technology, end user and region.
The kits segment from the product type segment accounted for 39.7% of HbA1c Testing type share
HbA1c testing provides a measure of average blood glucose levels over the past 2-3 months. This gives healthcare professionals a comprehensive view of a patient's long-term glucose control, as opposed to self-monitoring of blood glucose levels, which provides snapshots of current levels. HbA1c testing is one of the diagnostic tools for diabetes. It helps identify individuals with elevated average blood glucose levels over an extended period, aiding in the diagnosis of diabetes and prediabetes.
The demand for point-of-care testing is on the rise, driven by the need for faster results and increased convenience. Companies may launch HbA1c testing kits designed for use at the point of care, allowing for quicker assessments and immediate treatment adjustments. For instance, in October 2023, Healthyr, continuied to take action toward reinventing patient care with the launch of their six at-home tests currently available at Walmart. The six at-home tests include Healthyr's General Health Test, Cholesterol Test, HbA1c + Glucose Test, Thyroid Test, Cholesterol and Blood Sugar Test, and STI Test.
Additionally, in February 2023, Hurdle, a diagnostics-as-a-service company launched an at-home Hemoglobin A1c (HbA1c) Test that enables adult consumers to take a simple at-home blood sample to screen and monitor for diabetes. The developed by leading scientists, Hurdle’s testing technology offers leading accuracy and reliability and operates in partnership with labs that hold themselves to the highest testing standards. Thus above factors helps to accelerates the segment growth.
HbA1c Testing Market Geographical Analysis
North America accounted for 32.4% of the market share in 2025
North America is dominating the global HbA1c testing device market accounted for the largest market share, owing to rising incidences of diabetes. The United States is one of the top five countries with the highest diabetic population. The country has close to 100 million adults, diabetic and pre-diabetic. In 2021, according to the Centers for Disease Control and Prevention (CDC), more than 30 million people in the United States have diabetes. More than 84 million U.S. adults (over a third) have pre-diabetes. Diabetes is the 7th leading cause of death in the United States.
Type 2 diabetes accounts for about 90% to 95% of all diagnosed cases of diabetes; type 1 diabetes accounts for about 5%. The market growth of diabetic devices is directly proportional to the increasing diabetic population in the country. In the last 20 years, the number of adults diagnosed with diabetes has more than doubled as the American population has aged and become more overweight or obese. In the United States, 30% of the population lives with obesity, 7.5% of those have diabetes, and this rise of diseases helps to raise market growth in the region.
HbA1c Testing Market Competitive Landscape
The major global players in the market include Abbott Laboratories, Arkray, Inc, Bio-Rad Laboratories Inc, EKF Diagnostics Holdings Plc, Siemens Healthineers, PTS Diagnostics, Inc, Getein Biotech, Inc, Thermo Fisher Scientific Inc., Roche Diagnostics Corporation, Meril Life Sciences Pvt. Ltd among others.
HbA1c Testing Market Key Developments
July 2026: Siemens Healthineers expanded its Atellica CH, IM, and CI analyzer capabilities following CE marking for 24 capillary blood testing claims, including HbA1c. The development enables laboratories and hospitals to perform HbA1c testing using capillary blood samples while leveraging existing diagnostic infrastructure.
June 2026: HORIBA announced a strategic partnership with MEDCONN Diagnostics to expand the U.S. distribution of its MQ-3000 and MQ-8000 HbA1c analyzers. The collaboration strengthens access to high-performance liquid chromatography (HPLC)-based diabetes testing solutions across clinical laboratories.
May 2026: Tosoh Corporation launched its HLC-723GX2 automated glycohemoglobin analyzer, a compact HPLC-based system designed for faster HbA1c testing. The analyzer reduces measurement time from 2.2 minutes to 1.6 minutes per sample, supporting improved laboratory efficiency and higher testing capacity.
April 2026: PTS Diagnostics updated its A1CNow Self Check offering for home users, supporting convenient HbA1c monitoring through fingerstick blood samples. The system provides results within five minutes and supports decentralized diabetes monitoring without requiring laboratory-based testing.
March 12, 2026: Trinity Biotech commenced the commercial rollout of its next-generation Premier Hb9210 HbA1c column system in Brazil following local regulatory approval. The upgraded boronate-affinity technology is designed to reduce interference from hemoglobin variants and improve testing reliability.
January 6, 2026: Shanghai Medconn Medical Technology received FDA 510(k) clearance for its MQ-8000 and MQ-8000PT glycated hemoglobin testing systems. The HPLC-based analyzers support automated HbA1c measurement, expanding the availability of laboratory-based diabetes monitoring technologies.
Why Purchase the Report?
- To visualize the global HbA1c testing market segmentation based on product type, technology, end user, and regionas well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of HbA1c testing market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global HbA1c testing market report would provide approximately 64tables, 61figures and 186pages.
Target Audience 2025
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies

























































